Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy.


Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
04 2019
Historique:
received: 30 07 2018
revised: 05 11 2018
accepted: 05 11 2018
pubmed: 11 2 2019
medline: 25 2 2020
entrez: 11 2 2019
Statut: ppublish

Résumé

This study tested the hypothesis that the extent of left ventricular (LV) eccentric structural remodeling in heart failure with reduced ejection fraction (HFrEF) is directly associated with clinical event responses to cardiac resynchronization therapy (CRT). Whether the severity of LV structural remodeling influences CRT treatment effects is unknown. COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) trial data were analyzed retrospectively. Left ventricular internal dimensions at end diastole indexed by body surface area (LVEDDI) were measured pre-randomization by 2-dimensional echocardiography. LVEDDI values were stratified around the median value of 35 mm/m In the LVEDDI ≥35 mm/m Larger versus smaller LVEDDIs are associated with a reduction in ACM with CRT-P or CRT-D treatment, and with a more effective reduction in ACM/HFH for the combined CRT treatment groups.

Sections du résumé

OBJECTIVES
This study tested the hypothesis that the extent of left ventricular (LV) eccentric structural remodeling in heart failure with reduced ejection fraction (HFrEF) is directly associated with clinical event responses to cardiac resynchronization therapy (CRT).
BACKGROUND
Whether the severity of LV structural remodeling influences CRT treatment effects is unknown.
METHODS
COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) trial data were analyzed retrospectively. Left ventricular internal dimensions at end diastole indexed by body surface area (LVEDDI) were measured pre-randomization by 2-dimensional echocardiography. LVEDDI values were stratified around the median value of 35 mm/m
RESULTS
In the LVEDDI ≥35 mm/m
CONCLUSIONS
Larger versus smaller LVEDDIs are associated with a reduction in ACM with CRT-P or CRT-D treatment, and with a more effective reduction in ACM/HFH for the combined CRT treatment groups.

Identifiants

pubmed: 30738980
pii: S2213-1779(18)30838-2
doi: 10.1016/j.jchf.2018.11.004
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-290

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Fadi Shamoun (F)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: shamoun.fadi@mayo.edu.

Teresa De Marco (T)

Department of Medicine, Division of Cardiology, University of California Medical Center, San Francisco, California.

David DeMets (D)

Statistical Data Analysis Center, University of Wisconsin Madison, Wisconsin.

Chaoqun Mei (C)

Statistical Data Analysis Center, University of Wisconsin Madison, Wisconsin.

JoAnn Lindenfeld (J)

Department of Medicine, Division of Cardiology, Vanderbilt University, Nashville, Tennessee.

Leslie A Saxon (LA)

Department of Medicine, Division of Cardiology, University of Southern California, Los Angeles, California.

John P Boehmer (JP)

Department of Medicine, Division of Cardiology, Pennsylvania State University Medical Center, Hershey, Pennsylvania.

Jill Leigh (J)

Boston Scientific, St. Paul, Minnesota.

Patrick Yong (P)

Department of Medicine, Division of Cardiology, Temple University, Philadelphia, Pennsylvania.

Arthur M Feldman (AM)

Department of Medicine, Division of Cardiology and Cardiovascular Institute, University of Colorado, Boulder and Aurora, Colorado.

Michael R Bristow (MR)

Department of Medicine, Division of Cardiology and Cardiovascular Institute, University of Colorado, Boulder and Aurora, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH